Drugmaker Eli Lily is planning to invest up to $27 billion to build four new drug manufacturing sites in the United States, the company announced Wednesday.
The company said that three future US sites will focus on the production of active drugs. The fourth place focuses on injectable therapy.
Lily said the site has not yet been selected, but the new location will create 3,000 advanced jobs and employ 10,000 construction workers over the next five years.
Lily had invested $23 billion in 2020-2024 as it had expanded to new manufacturing sites in Wisconsin and North Carolina and home to Indiana.
Trump said he is putting pressure on manufacturers and other industries to return manufacturing to the US, and earlier this month he is considering a 25% tariff on imports of drugs and products such as automobiles and semiconductors.
“Our confidence positions us to help reuse domestic manufacturing that benefits hard-working American families and increase exports of drugs made in the United States,” Lily's chairman and CEO David A. Lix said in a statement.
Rix believes that Trump's tax cuts helped the company promote domestic investment, calling for an extension, an important priority for Trump and Congressional Republicans. Two separate budget resolutions are underway in the House and Senate as part of starting the legislative process that lawmakers want to use to enact Trump's agenda.
Lily has been working to boost manufacturing capacity to meet the massive demands of the blockbuster diabetes and weight loss drugs Zepbound and Munjaro.
The drug has been in short supply for years due to a lack of manufacturing capacity, but the Food and Drug Administration recently removed tilzepatide, the popular name for the drug, from the shortage list.
